Clinical Trial

Doxycycline in Type II Diabetes

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated March 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-24; most recent amendment 2025-04-03.
Status change: Not Yet Recruiting → Recruiting 2024-07-13
Trial Details
NCT Number NCT06329882
Lead Sponsor Mostafa Bahaa
Conditions Diabetes Mellitus, Type 2
Enrollment 60 participants
Start Date 2024-03-30
Primary Completion 2026-03-20 (estimated)
Study Completion 2026-04-20 (estimated)
Updated on ClinicalTrials.gov 2025-04-04